Skip to main content

Advertisement

SpringerLink
Log in

The Future of Chemotherapy in the Era of Personalized Medicine

  • Systemic Therapy (J Cortes, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Chemotherapy still represents the mainstay of therapy for many breast cancer patients. Indeed, it is the only available option for the treatment of triple-negative disease. Moreover, targeted agents, in particular anti-HER2 compounds, show the highest efficacy when combined with chemotherapy. Research efforts should therefore continue to investigate new chemotherapeutic drugs, with the attempt to increase efficacy and reduce toxicity. Similarly to targeted drugs, cytotoxic compounds should be developed in the context of personalized medicine, by adopting tools including high-throughput technologies to select sensitive patient subsets. Indeed, it seems clear by now that great advances in the general, unselected breast cancer population are no longer possible. The attention has to be moved to smaller breast cancer disease groups and this will have obvious implications in clinical trials design and conception in the next future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Berry DA, Cronin KA, Plevritis SK, et al. Cancer Intervention and Surveillance Modeling Network (CISNET) collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.

    Article  PubMed  CAS  Google Scholar 

  3. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighboring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ. 2011;343:d4411.

    Article  PubMed  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet. 2012;379:432–44.

    Google Scholar 

  6. Jacquin JP, Jones S, Magné N, et al. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. Breast Cancer Res Treat. 2012;134:903–13.

    Article  PubMed  CAS  Google Scholar 

  7. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012. Last accessed October 2012.

  8. Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009;14:645–56.

    Article  PubMed  CAS  Google Scholar 

  9. Oostendorp LJ, Stalmeier PF, Donders AR, et al. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol. 2011;12:1053–61.

    Article  PubMed  CAS  Google Scholar 

  10. Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101:1174–81.

    Article  PubMed  CAS  Google Scholar 

  11. Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102:1845–54.

    Article  PubMed  CAS  Google Scholar 

  12. Swain SM, Tang G, Geyer CE, et al. NSABP B-38: definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. [abstr LBA1000]. Presented at the 2012 ASCO Annual Meeting. Chicago, Illinois, USA; June 1–5, 2012.

  13. Poole CJ, Hiller L, Howard HC, et al. tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). [Abstract 506] Presented at the 2008 ASCO Annual Meeting. Chicago, Illinois, USA, May 30–June 3, 2008.

  14. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30:11–8.

    Article  PubMed  CAS  Google Scholar 

  15. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.

    Article  PubMed  CAS  Google Scholar 

  16. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–44.

    Article  PubMed  Google Scholar 

  17. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.

    Article  PubMed  CAS  Google Scholar 

  18. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.

    Article  PubMed  CAS  Google Scholar 

  19. Esserman LJ, Berry DA, Demichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30:3242–9.

    Article  PubMed  Google Scholar 

  20. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.

    Article  Google Scholar 

  21. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.

    Article  PubMed  Google Scholar 

  22. Houssami N, Macaskill P, von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012.

  23. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

    Article  PubMed  CAS  Google Scholar 

  24. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol. 2010;11:55–65.

    Article  PubMed  CAS  Google Scholar 

  25. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010;120:655–61.

    Article  PubMed  CAS  Google Scholar 

  26. O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triplenegative breast cancer. N Engl J Med. 2011;364:205–14.

    Article  PubMed  Google Scholar 

  27. O’Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)). [Abstract 1007]. Presented at the 2011 ASCO Annual Meeting. Chicago, Illinois, USA; June 3–7, 2011.

  28. Glendenning J, Tutt A. PARP inhibitors–current status and the walk towards early breast cancer. Breast. 2011;20 Suppl 3:S12–9.

    Article  PubMed  Google Scholar 

  29. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab vs paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  PubMed  CAS  Google Scholar 

  30. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310–20.

    Article  PubMed  CAS  Google Scholar 

  31. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299–309.

    Article  Google Scholar 

  32. Baselga J, Stemmer S, Pego A, et al. Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized Phase II BALI-1 Trial. Presented at the 33rd San Antonio Breast cancer Symposium. San Antonio, Texas, USA; December 8–12, 2010.

  33. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615–23.

    Article  PubMed  CAS  Google Scholar 

  34. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010;28:5110–5.

    Article  PubMed  CAS  Google Scholar 

  35. Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011;17:6905–13.

    Article  PubMed  CAS  Google Scholar 

  36. Guarneri V, Barbieri E, Dieci MV, et al. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010;36 Suppl 3:S62–6.

    Article  PubMed  CAS  Google Scholar 

  37. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.

    PubMed  CAS  Google Scholar 

  38. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–44.

    PubMed  CAS  Google Scholar 

  39. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.

    Article  PubMed  CAS  Google Scholar 

  40. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241–51.

    Article  PubMed  CAS  Google Scholar 

  41. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  PubMed  CAS  Google Scholar 

  42. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.

    Article  PubMed  CAS  Google Scholar 

  43. Hamberg P, Bos MM, Braun HJ, et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer. 2011;11:103–13.

    Article  PubMed  CAS  Google Scholar 

  44. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.

    PubMed  Google Scholar 

  45. Perez EA, Suman VJ, Davidson NE, et al. Sequential vs concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29:4491–7.

    Article  PubMed  CAS  Google Scholar 

  46. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29:264–71.

    Article  PubMed  CAS  Google Scholar 

  47. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:976–83.

    Article  PubMed  CAS  Google Scholar 

  48. von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273–81.

    Article  Google Scholar 

  49. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008;19:1068–74.

    Article  PubMed  CAS  Google Scholar 

  50. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26:2999–3005.

    Article  PubMed  CAS  Google Scholar 

  51. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.

    Article  PubMed  CAS  Google Scholar 

  52. Burris 3rd HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398–405.

    Article  PubMed  CAS  Google Scholar 

  53. Krop IE, Lorusso P, Miller KD, et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-Positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30:3234–41.

    Article  PubMed  CAS  Google Scholar 

  54. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-Positive advanced breast cancer. N Engl J Med. 2012.

  55. Hurvitz SA, Dirix L, Kocsis J, et al. Trastuzumab emtansine (T-DM1) vs trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multiventer, open-label phase II study 5TDM4450g/BO21976) [Abstract 5001]. Presented at: European Multidisciplinary Cancer Congress (ECCO/ESMO). Stockholm, Sweden; September 23–27, 2011.

  56. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.

    Article  PubMed  CAS  Google Scholar 

  57. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicenter, phase III trial. Lancet. 2012;379:633–40.

    Article  PubMed  CAS  Google Scholar 

  58. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase II trial. Lancet Oncol. 2012;13:25–32.

    Article  PubMed  CAS  Google Scholar 

  59. Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30:1989–95.

    Article  PubMed  CAS  Google Scholar 

  60. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole vs anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized TAnDEM study. J Clin Oncol. 2009;27:5529–37.

    Article  PubMed  CAS  Google Scholar 

  61. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole vs letrozole and placebo as first-line therapy for postmenopausal hormone-receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538–46.

    Article  PubMed  CAS  Google Scholar 

  62. Alvarez RH, Guarneri V, Icli F, et al. Bevacizumab treatment for advanced breast cancer. Oncologist. 2011;16:1684–97.

    Article  PubMed  CAS  Google Scholar 

  63. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30(5 Suppl 16):117–24.

    Article  PubMed  CAS  Google Scholar 

  64. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.

    Article  PubMed  CAS  Google Scholar 

  65. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent, or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.

    Article  PubMed  CAS  Google Scholar 

  66. O’Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data fron 3 randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). [Abstract 1005]. Presented at the 2010 ASCO Annual Meeting. Chicago, Illinois, USA; June 4–8, 2010.

  67. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305:487–94.

    Article  PubMed  CAS  Google Scholar 

  68. Cortes J, Calvo V, Ramírez-Merino N, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol. 2012;23:1130–7.

    Article  PubMed  CAS  Google Scholar 

  69. Food and Drug Administration. Proposal to withdraw approval for the breast cancer indication for AVASTIN (bevacizumab). Decision of the commissioner. November 18, 2011. Available at: http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf. Accessed October 8, 2012.

  70. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009;27:11–5.

    Article  PubMed  CAS  Google Scholar 

  71. Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009;20:616–24.

    Article  PubMed  CAS  Google Scholar 

  72. Baselga J, Segalla JG, Roche H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 2012;30:1484–91.

    Article  PubMed  CAS  Google Scholar 

  73. Gradishar W, Kaklamani V, Prasad Sahoo T, et al. A double-blind, randomized, placebo-controlled, phase IIb study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). [Abstract 44]. Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, USA; December 9–13, 2009.

  74. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast. 2011;20 Suppl 3:S56–60.

    Article  PubMed  Google Scholar 

  75. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008;26:4899–905.

    Article  PubMed  CAS  Google Scholar 

  76. Denduluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Cancer. 2011;11:139–45.

    Article  PubMed  CAS  Google Scholar 

  77. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistantmetastatic breast cancer. J Clin Oncol. 2007;25:3399–406.

    Article  PubMed  CAS  Google Scholar 

  78. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407–14.

    Article  PubMed  CAS  Google Scholar 

  79. • Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–7. Positive phase III trial of ixabepilone plus capecitabine in pretreated patients..

    Article  PubMed  CAS  Google Scholar 

  80. • Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256–63. Positive phase III trial of ixabepilone plus capecitabine in pretreated patients..

    Article  PubMed  CAS  Google Scholar 

  81. Guarneri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother. 2012;13:395–406.

    Article  PubMed  CAS  Google Scholar 

  82. Gradishar WJ, Krasnojon D, Cheporov S. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611–9.

    Article  PubMed  CAS  Google Scholar 

  83. Gradishar WJ, Krasnojon D, Cheporov S, et al. Albumin-bound paclitaxel (ab-pac) vs docetaxel for first-line treatment of metastatic breast cancer (MBC): final overall survival (OS) analysis of a randomized phase II trial. [Abstract 275]. Presented at the 2011 ASCO Breast cancer Symposium. San Francisco, California, USA; September 8–10,2011.

  84. • Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803. Phase III trial demonstrating superiority of 3-weekly nab-paclitaxel vs 3-weekly standard paclitaxel..

    Article  PubMed  CAS  Google Scholar 

  85. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23:5983–92.

    Article  PubMed  CAS  Google Scholar 

  86. Rugo HS, Barry WT, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared with weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). [Abstract CRA1002]. Presented at the 2012 ASCO Annual Meeting. Chicago, Illinois, USA; June 1–5, 2012.

  87. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 in supression of microtubule growth. Mol Cancer Ther. 2005;4:1086–95.

    Article  PubMed  CAS  Google Scholar 

  88. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the Halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28:3922–8.

    Article  PubMed  CAS  Google Scholar 

  89. •• Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy vs treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase III open label randomized study. Lancet. 2011;377:914–23. Phase III trial demonstrating a survival advantage in the late-line setting for eribulin, compared with treatment of physician’s choice..

    Article  PubMed  CAS  Google Scholar 

  90. “EISAI announces preliminary results of phase III study (study 301) of anticancer agent halaven® vs capecitabine in locally advanced or metastatic breast cancer” July 10, 2012. Available at http://www.eisai.com/news/enews201244pdf.pdf.

  91. Kruczynski A, Poli M, Dossi R, et al. Antiangiogenic, vascular-disrupting and antimetastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42:2821–32.

    Article  PubMed  CAS  Google Scholar 

  92. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer. 2006;95:1161–6.

    Article  PubMed  CAS  Google Scholar 

  93. Campone M, Isambert N, Bourbouloux E, et al. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol. 2012;69:871–9.

    Article  PubMed  CAS  Google Scholar 

  94. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer. 2006;94:1610–4.

    Article  PubMed  CAS  Google Scholar 

  95. Tedesco KL, Blum JL, Goncalves A, Jet, et al. Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). [Abstract 1125]. Presented at the 2011 ASCO Annual Meeting. Chicago, Illinois, USA; June 3–7, 2011.

  96. Awada A, Cortes J, Martin M, et al. A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression. [Abstract TPS652]. Presented at the 2012 ASCO Annual Meeting. Chicago, Illinois, USA; June 1–5, 2012.

  97. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–9.

    Article  PubMed  Google Scholar 

  98. Trudeau ME, Clemons MJ, Provencher L, et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol. 2009;27:5906–10.

    Article  PubMed  CAS  Google Scholar 

  99. Wolff AC, Wang M, Li H, et al. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat. 2010;121:111–20.

    Article  PubMed  CAS  Google Scholar 

  100. Chia S, Clemons M, Martin L-A, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006;24:2773–8.

    Article  PubMed  CAS  Google Scholar 

  101. Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, et al. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann Oncol. 2012;23:1780–8. 2011.

    Article  PubMed  CAS  Google Scholar 

  102. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294–300.

    Article  PubMed  CAS  Google Scholar 

  103. Kadra G, Finetti P, Toiron Y, et al. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Res Treat. 2012;132:1035–47.

    Article  PubMed  CAS  Google Scholar 

  104. Pean E, Klaar S, Berglund EG, et al. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res. 2012;18:4491–7.

    Article  PubMed  CAS  Google Scholar 

  105. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29:2144–9.

    Article  PubMed  Google Scholar 

  106. Rugo RS, Campone M, Amadori A, et al. Randomized phase II study of weekly vs every 3 week ixabepilone plus bevacizumab vs paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer: final results. [Abstract 1040]. Presented at the 2010 ASCO Annual Meeting. Chicago, Illinois, USA; June 4–8, 2010.

  107. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7:850–6.

    Article  PubMed  CAS  Google Scholar 

  108. Fumoleau P, Cortés-Funes H, Taleb AB, et al. Phase II study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol. 2009;32:375–80.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

M.V. Dieci: none; V. Guarneri: none; P. Conte: board membership with Roche, GlaxoSmithKline, and Novartis; consultant to Roche, GlaxoSmithKline, and Novartis; research funding from GlaxoSmithKline and Roche; and payment for lectures including service on speakers’ bureaus from Roche, GlaxoSmithKline, and Novartis.

Author information

Authors and Affiliations

  1. Department of Oncology, Hematology and Respiratory Diseases, Modena University Hospital, via del Pozzo 71, 41124, Modena, Italy

    Maria Vittoria Dieci, Valentina Guarneri & PierFranco Conte

Authors
  1. Maria Vittoria Dieci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Guarneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. PierFranco Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to PierFranco Conte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dieci, M.V., Guarneri, V. & Conte, P. The Future of Chemotherapy in the Era of Personalized Medicine. Curr Breast Cancer Rep 5, 57–68 (2013). https://doi.org/10.1007/s12609-012-0094-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-012-0094-4

Keywords

Search

Navigation